Efficacy and safety of tralokinumab monotherapy in North American adult patients with moderate-to-severe atopic dermatitis: A subanalysis of the ECZTRA 2 trial

被引：0
|
作者：
Wiseman, Marni [1 ,2 ,3 ]
Armstrong, April W. [4 ]
Soung, Jennifer [5 ,6 ]
Albrecht, Lorne [3 ,7 ]
Lomaga, Mark [3 ,8 ]
Papp, Kim A. [3 ,9 ]
机构：
[1] Univ Manitoba, Dept Med, Winnipeg, MB, Canada
[2] Univ Manitoba, Dept Dermatol, Winnipeg, MB, Canada
[3] Prob Med Res, Waterloo, ON, Canada
[4] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[5] Southern Calif Dermatol, Santa Ana, CA USA
[6] Harbor Univ Calif Los Angeles, Los Angeles, CA USA
[7] Enverus Med Res, Surrey, BC, Canada
[8] DermEdge Res, Mississauga, ON, Canada
[9] K Papp Clin Res, Waterloo, ON, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
28186
引用
收藏
页码：AB178 / AB178
页数：1
相关论文
共 50 条
  • [31] Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis
    Devjani, Shivali
    Engel, Priya, V
    Javadi, Sogol S.
    Smith, Brandon
    Wu, Jashin J.
    LANCET, 2023, 402 (10415): : 1833 - 1834
  • [32] Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis
    Bridgeman, Sarah G.
    Martino, Anna K.
    Strowd, Lindsay C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (18) : 2153 - 2159
  • [33] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Xu, Xinghua
    Zheng, Yi
    Zhang, Xin
    He, Yanling
    Li, Chengxin
    ONCOTARGET, 2017, 8 (65) : 108480 - 108491
  • [34] Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis
    Khattri, S.
    Brunner, P. M.
    Garcet, S.
    Finney, R.
    Cohen, S. R.
    Oliva, M.
    Dutt, R.
    Fuentes-Duculan, J.
    Zheng, X.
    Li, X.
    Bonifacio, K. M.
    Kunjravia, N.
    Coats, I.
    Cueto, I.
    Gilleaudeau, P.
    Sullivan-Whalen, M.
    Suarez-Farinas, M.
    Krueger, J. G.
    Guttman-Yassky, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S41 - S41
  • [35] Efficacy and safety of 611 for the treatment of moderate-to-severe atopic dermatitis in adults
    Zhang, Jianzhong
    Zhao, Yan
    Zhou, Qinghong
    Xu, Yuyu
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I54 - I55
  • [36] Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, Emma
    Weidinger, Stephan
    Simpson, Eric
    Gooderham, Melinda
    Irvine, Alan
    Spelman, Lynda
    Silverberg, Jonathan
    Elmaraghy, Hany
    DeLuca-Carter, Louise
    Piruzeli, Maria Lucia Buziqui
    Hu, Chaoran
    Yang, Fan Emily
    Pierce, Evangeline
    Bardolet, Laia
    Thaci, Diamant
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II3 - II4
  • [37] Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
    Soehoel, Anders
    Larsen, Malte Selch
    Timmermann, Stine
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (08): : 910 - 921
  • [38] The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
    Bashrahil, Bader
    Alzahrani, Ziyad
    Samarkandy, Sahal
    Aman, Abdullah
    Jfri, Abdulhadi
    FRONTIERS IN MEDICINE, 2023, 9
  • [39] Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial
    Beck, Lisa A.
    Bieber, Thomas
    Weidinger, Stephan
    Tauber, Marie
    Saeki, Hidehisa
    Irvine, Alan D.
    Eichenfield, Lawrence F.
    Werfel, Thomas
    Arlert, Petra
    Jiang, Li
    Ropke, Mads
    Paller, Amy S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (04) : 816 - 823
  • [40] Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis
    Salman, Andac
    Sengun, Ozlem Apti
    Aktas, Meryem
    Taskapan, Oktay
    DERMATOLOGIC THERAPY, 2022, 35 (01)
12345